Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-YTH 24.5 is a radiopharmaceutical composed of technetium-99m, a metastable nuclear isomer of technetium-99 used as a gamma-emitting radionuclide, conjugated to YTH 24.5, which is a murine monoclonal antibody. The resulting radioimmunoconjugate is designed for diagnostic imaging, likely in oncological or immunoscintigraphy applications. Technetium-99m serves as a gamma emitter detectable by SPECT imaging, enabling visualization of targets bound by the antibody[1][4]. The specificity of YTH 24.5 typically depends on its antigen target, which is not detailed in the retrieved literature, but this class of agents is primarily used for tumor or cell-surface marker imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-YTH 24.5.